{"id":29673,"date":"2017-12-01T10:09:47","date_gmt":"2017-12-01T09:09:47","guid":{"rendered":"http:\/\/www.invarena.cz\/?p=29673"},"modified":"2017-12-01T10:09:47","modified_gmt":"2017-12-01T09:09:47","slug":"vzp-navrhuje-aby-se-na-nove-lecbe-pacientu-podileli-vyrobci-leku","status":"publish","type":"post","link":"https:\/\/www.invarena.cz\/?p=29673","title":{"rendered":"VZP navrhuje, aby se na nov\u00e9 l\u00e9\u010db\u011b pacient\u016f pod\u00edleli v\u00fdrobci l\u00e9k\u016f"},"content":{"rendered":"<p><strong>V\u0161eobecn\u00e1 zdravotn\u00ed poji\u0161\u0165ovna (VZP) navrhuje, aby se na l\u00e9\u010db\u011b pacient\u016f, kter\u00e1 nen\u00ed hrazena z ve\u0159ejn\u00e9ho zdravotn\u00edho poji\u0161t\u011bn\u00ed, pod\u00edlely farmaceutick\u00e9 firmy. V\u011bt\u0161inou jde o drah\u00e9 modern\u00ed l\u00e9ky. <\/strong><!--more--><\/p>\n<p>Podle n\u00e1m\u011bstka \u0159editele Petra Ho\u0148ka by poji\u0161\u0165ovna mohla platit a\u017e v p\u0159\u00edpad\u011b, \u017ee se prok\u00e1\u017ee \u00fa\u010dinnost nov\u00fdch l\u00e9k\u016f. S n\u011bkolika firmami si poji\u0161\u0165ovna tento postup u\u017e dohodla. Nyn\u00ed zdravotn\u00ed poji\u0161\u0165ovny tuto p\u00e9\u010di plat\u00ed na v\u00fdjimku v z\u00e1kon\u011b o ve\u0159ejn\u00e9m zdravotn\u00edm poji\u0161t\u011bn\u00ed. VZP na ni loni dala p\u0159es miliardu korun. Podle v\u00fdkonn\u00e9ho \u0159editele Asociace inovativn\u00edho farmaceutick\u00e9ho pr\u016fmyslu Jakuba Dvo\u0159\u00e1\u010dka syst\u00e9m sd\u00edlen\u00ed rizika v \u010cesku u\u017e funguje.<\/p>\n<p>Zdravotn\u00ed poji\u0161\u0165ovny dostaly loni p\u0159es 21.500 \u017e\u00e1dost\u00ed o proplacen\u00ed nehrazen\u00e9 l\u00e9\u010dby. Schv\u00e1lily asi 90 procent z nich. Podle Ho\u0148ka to u VZP v ostatn\u00edch p\u0159\u00edpadech z\u00e1kon neumo\u017e\u0148oval. &#8222;L\u00e9ka\u0159i \u017e\u00e1daj\u00ed poji\u0161\u0165ovny, aby jejich pacient\u016fm uhradily l\u00e9\u010dbu, kter\u00e1 podle z\u00e1kona hradit nelze,&#8220; vysv\u011btlil.<\/p>\n<p>Kter\u00e9 l\u00e9ky a procedury budou hrazen\u00e9, rozhoduje St\u00e1tn\u00ed \u00fastav pro kontrolu l\u00e9\u010div (S\u00daKL) na z\u00e1klad\u011b \u017e\u00e1dosti v\u00fdrobce a posouzen\u00ed jejich \u00fa\u010dink\u016f. N\u011bkter\u00e9 firmy ale S\u00daKL ani nepo\u017e\u00e1daj\u00ed, p\u0159esto l\u00e9ka\u0159i o proplacen\u00ed jejich l\u00e9k\u016f \u017e\u00e1daj\u00ed.<\/p>\n<p>Podle Dvo\u0159\u00e1\u010dka farmaceutick\u00e9 firmy nejsou do \u0159\u00edzen\u00ed nijak zapojeny. &#8222;Farmaceutick\u00e1 spole\u010dnost se mohla rozhodnout do \u010cesk\u00e9 republiky s p\u0159\u00edpravkem nevstoupit kv\u016fli zdej\u0161\u00edm n\u00edzk\u00fdm cen\u00e1m, p\u0159\u00edpadn\u011b kv\u016fli slo\u017eitosti, zdlouhavosti a n\u00e1kladnosti schvalovac\u00edho procesu. Anebo o vstup do syst\u00e9mu po\u017e\u00e1dala, ale o \u017e\u00e1dosti je\u0161t\u011b regul\u00e1tor nerozhodl,&#8220; vysv\u011btlil \u0159editel asociace.<\/p>\n<p>Pokud \u00fahrada p\u0159iznan\u00e1 nen\u00ed, mohou lid\u00e9 ve v\u00fdjime\u010dn\u00fdch p\u0159\u00edpadech po\u017e\u00e1dat prost\u0159ednictv\u00edm l\u00e9ka\u0159e poji\u0161\u0165ovnu o v\u00fdjime\u010dn\u00e9 uhrazen\u00ed podle paragrafu 16 v z\u00e1kon\u011b o ve\u0159ejn\u00e9m zdravotn\u00edm poji\u0161t\u011bn\u00ed. Uv\u00e1d\u00ed, \u017ee zdravotn\u00ed poji\u0161\u0165ovna hrad\u00ed nehrazen\u00e9 slu\u017eby &#8222;ve v\u00fdjime\u010dn\u00fdch p\u0159\u00edpadech, je-li poskytnut\u00ed jedinou mo\u017enost\u00ed z hlediska zdravotn\u00edho stavu poji\u0161t\u011bnce&#8220;.<\/p>\n<p>Za p\u011bt let podle Ho\u0148ka \u017e\u00e1dost\u00ed p\u0159ibylo o 180 procent, n\u00e1klady stouply z 347 milion\u016f korun v roce 2013 na lo\u0148skou v\u00edce ne\u017e miliardu. Situace je podle Ho\u0148ka d\u00e1l neudr\u017eiteln\u00e1, situaci mus\u00ed vy\u0159e\u0161it zm\u011bna z\u00e1kona.<\/p>\n<p>N\u00e1m\u011bstek citoval studii z odborn\u00e9ho \u010dasopisu British Medical Journal, kter\u00e1 hodnotila 48 l\u00e9\u010debn\u00fdch p\u0159\u00edpravk\u016f, kter\u00e9 vstoupily na trh p\u0159ed t\u0159emi a\u017e osmi lety. U 49 procent diagn\u00f3z se neprok\u00e1zalo, \u017ee inovativn\u00ed l\u00e9ky prodlu\u017eovaly \u017eivot nebo zvy\u0161ovaly jeho kvalitu.<\/p>\n<p>Podle asociace firem \u010dl\u00e1nek kritizovala \u0159ada autorit v\u010detn\u011b Evropsk\u00e9 l\u00e9kov\u00e9 agentury. Ve\u0161ker\u00e9 l\u00e9\u010div\u00e9 p\u0159\u00edpravky dostupn\u00e9 v \u010cesku podle Dvo\u0159\u00e1\u010dka proch\u00e1zej\u00ed schv\u00e1len\u00edm, je tedy prok\u00e1z\u00e1no, \u017ee jsou \u00fa\u010dinn\u00e9 a bezpe\u010dn\u00e9. &#8222;British Medical Journal sv\u00fdm \u010dl\u00e1nkem zpochybnil pr\u00e1ci t\u00e9to nejvy\u0161\u0161\u00ed evropsk\u00e9 \u00fa\u0159edn\u00ed autority v oblasti l\u00e9\u010div,&#8220; dodal. Byla v n\u00ed podle n\u011bj i \u0161patn\u011b pou\u017eit\u00e1 metodika.<\/p>\n<p>Poji\u0161\u0165ovna proto navrhuje princip sd\u00edlen\u00ed rizik mezi farmaceutick\u00fdmi firmami, kter\u00e9 uv\u00e1d\u011bj\u00ed nov\u00e9 l\u00e9ky na trh, a poji\u0161\u0165ovnami. Pokud by se neprok\u00e1zala \u00fa\u010dinnost l\u00e9\u010dby, poji\u0161\u0165ovna by ji v\u00fdrobci neproplatila. Podle Ho\u0148ka v\u00fdrobce \u010dasto uv\u00e1d\u00ed, dokdy byl se m\u011bl o\u010dek\u00e1van\u00fd \u00fa\u010dinek l\u00e9ku dostavit, p\u0159\u00edpadn\u011b by \u0161lo \u00fa\u010dinek posuzovat podle pr\u016fm\u011brn\u00e9 doby do\u017eit\u00ed pacienta s danou nemoc\u00ed. Podle Dvo\u0159\u00e1\u010dka se princip sd\u00edlen\u00ed rizik u\u017e uplat\u0148uje.<\/p>\n<p>&#8222;Tato mo\u017enost umo\u017e\u0148uje to zvy\u0161ovat dostupnost l\u00e9\u010dby. Ale vzhledem k tomu, jak je v \u010cR proces dlouh\u00fd, se nelze divit tomu, \u017ee pacienti hledaj\u00ed cesty, jak se k l\u00e9\u010db\u011b dostat,&#8220; dodal.<\/p>\n<p>Naprostou v\u011bt\u0161inu \u017e\u00e1dost\u00ed na paragraf 16 tvo\u0159\u00ed podle poji\u0161\u0165oven takzvan\u00e1 biologick\u00e1 l\u00e9\u010dba, kterou se l\u00e9\u010d\u00ed jen ve specializovan\u00fdch centrech. Tyto modern\u00ed l\u00e9ky p\u016fsob\u00ed na molekuly a na pochody, kter\u00e9 jsou typick\u00e9 pro bu\u0148ky spojen\u00e9 s n\u00e1dorov\u00fdm nebo autoimunitn\u00edm onemocn\u011bn\u00edm a ve zdrav\u00fdch bu\u0148k\u00e1ch se bu\u010f nevyskytuj\u00ed, nebo jen v mal\u00e9 m\u00ed\u0159e. L\u00e9\u010diva tak zlep\u0161uj\u00ed \u010di opravuj\u00ed schopnost sebeobrany organismu. Pou\u017e\u00edvaj\u00ed se nap\u0159\u00edklad pro l\u00e9\u010dbu autoimunitn\u00edch chorob, jako jsou lup\u00e9nka, revmatoidn\u00ed artritida a roztrou\u0161en\u00e1 skler\u00f3za, nebo rakoviny. U jednoho pacienta stoj\u00ed a\u017e miliony ro\u010dn\u011b, n\u00e1klady loni byly p\u0159es deset miliard korun.<\/p>\n<p>P\u0159\u00edpady, kdy poji\u0161\u0165ovny l\u00e9\u010dbu zam\u00edtnou, proto\u017ee pacient nespln\u00ed v\u0161echna krit\u00e9ria pro jej\u00ed propl\u00e1cen\u00ed, jsou \u010dasto medializovan\u00e9. Jen letos jich bylo n\u011bkolik a t\u00fdkaly se r\u016fzn\u00fdch zdravotn\u00edch poji\u0161\u0165oven. V n\u011bkter\u00fdch p\u0159\u00edpadech se pacienti proplacen\u00ed p\u00e9\u010de pot\u00e9 domohli, dal\u0161\u00ed se za\u010d\u00ednaj\u00ed se sv\u00fdmi poji\u0161\u0165ovnami soudit.<\/p>\n","protected":false},"excerpt":{"rendered":"<div class=\"mh-excerpt\"><p>V\u0161eobecn\u00e1 zdravotn\u00ed poji\u0161\u0165ovna (VZP) navrhuje, aby se na l\u00e9\u010db\u011b pacient\u016f, kter\u00e1 nen\u00ed hrazena z ve\u0159ejn\u00e9ho zdravotn\u00edho poji\u0161t\u011bn\u00ed, pod\u00edlely farmaceutick\u00e9 firmy. V\u011bt\u0161inou jde o drah\u00e9 modern\u00ed <a class=\"mh-excerpt-more\" href=\"https:\/\/www.invarena.cz\/?p=29673\" title=\"VZP navrhuje, aby se na nov\u00e9 l\u00e9\u010db\u011b pacient\u016f pod\u00edleli v\u00fdrobci l\u00e9k\u016f\">[&#8230;]<\/a><\/p>\n<\/div>","protected":false},"author":1,"featured_media":24197,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-29673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nezarazene"],"_links":{"self":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/posts\/29673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29673"}],"version-history":[{"count":0,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/posts\/29673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=\/wp\/v2\/media\/24197"}],"wp:attachment":[{"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.invarena.cz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}